bioMérieux

France’s bioMérieux has secured European CE marking for three fully automated immunoassays for dengue, the company announced Wednesday.

Performed on the company’s Vidas family platforms, the Vidas Dengue NS1 Ag, Anti-Dengue IgM and Anti-Dengue IgG are “cost-effective and suitable for low- and middle-income countries,” according to the press release.

The company plans to add a chikungunya assay to its diagnostic offerings, per the announcement.

Twelve leading pharma companies released second-quarter 2020 financial results in July, and one Japanese firm (with a fiscal year ending in March) reported first-quarter numbers.

(Figures exclude exchange rate and portfolio changes where applicable.)

Leading the pack, AstraZeneca reported an 11% hike in total revenues to reach $6.3 billion in the quarter—slightly above consensus estimates. Amid the coronavirus lockdown, the British drugmaker saw strong product sales as its…